The evolving therapeutic landscape of antibody-drug conjugates in breast cancer.

ABSTRACT:

Introduction

Antibody-drug conjugates (ADCs) are a relatively new class of anti-cancer therapies approved for a number of malignancies, including breast cancer. Their unique structure, consisting of a monoclonal antibody connected via a linker to a toxic payload, combines characteristics of both targeted therapy and chemotherapy.

Areas covered

In this review, we discuss the unique molecular structure and pharmacologic principles of ADCs and present the clinical efficacy and relevant toxicities of ADCs both approved and in development. While HER2 is the most studied target with approved agents for both HER2-positive and HER2-low expressing tumors, novel targets in HER2-negative disease have expanded our therapeutic capabilities significantly.

Expert opinion

ADCs are a

SUBMITTER: Chen N 

PROVIDER: S-EPMC9833603 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature